SCHEMBL9475348

SCHEMBL9475348

COc1cc(OC(F)(F)F)cc2sc(N)nc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.54
HSD17B10 Q99714 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
CYP1A2 P05177 2/20 0.54
LMNA P02545 2/20 0.54
TP53 P04637 2/20 0.54
GAA P10253 2/20 0.54
SCN4A P35499 2/20 0.54
GMNN O75496 1/20 0.54
USP2 O75604 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
CYP2C9 P11712 1/20 0.54
PKM P14618 1/20 0.54
ALOX15 P16050 1/20 0.54
NFKB1 P19838 1/20 0.54
SLC6A2 P23975 1/20 0.54
BLM P54132 1/20 0.54
PMP22 Q01453 1/20 0.54
SLC6A3 Q01959 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9722840 0.85 CYP3A4 (0.58) CYP3A4HSD17B10CYP1A2LMNATP53
SCHEMBL9185915 0.82 CYP3A4 (0.56) CYP3A4HSD17B10NPC1RAB9ACYP1A2
SCHEMBL9475114 0.82 HSD17B10 (0.57) CYP3A4HSD17B10NPC1RAB9ACYP1A2
SCHEMBL9474741 0.82 CYP3A4 (0.59) CYP3A4HSD17B10NPC1RAB9ACYP1A2
Bromide SCHEMBL9189616 0.81 CYP3A4 (0.55) CYP3A4HSD17B10NPC1RAB9ACYP1A2
SCHEMBL9188493 0.80 CYP3A4 (0.54) CYP3A4HSD17B10NPC1RAB9ACYP1A2
SCHEMBL9476104 0.79 CYP3A4 (0.52) CYP3A4HSD17B10NPC1RAB9ACYP1A2
SCHEMBL21395394 0.77 CYP3A4 (0.57) CYP3A4HSD17B10NPC1RAB9ACYP1A2
SCHEMBL28795289 0.77 CYP3A4 (0.60) CYP3A4HSD17B10RAB9ACYP1A2LMNA
SCHEMBL29803040 0.77 CYP3A4 (0.60) CYP3A4HSD17B10RAB9ACYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5236940-A Administering for treatment of medical conditions associated with the effects of glutamate; glutamate-induced convulsions; schizophrenia; sleep disorders RHONE-POULENC SANTE (FR) 1993-08-17 US disclosed